Importantly, our model (Fig. 1I) rendered the PI3K/Akt/mTOR pathway as an interesting target for an experimental therapy in models of HNPP and CMT1A. The gene discussed is AKT1; the disease is hereditary neuropathy with liability to pressure palsies.